Gene · 23091
Papers1,599
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 1,599
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myeloma. | Blood Sci | 2023 | 37546707 | PubTator, text mining | PubMed |
| Using integrated analysis from multicentre studies to identify RNA methylation-related lncRNA risk stratification systems for glioma. | Cancer Cell Int | 2023 | 37542290 | PubTator, text mining | PubMed |
| ZC3H13 reduced DUOX1-mediated ferroptosis in laryngeal squamous cell carcinoma cells through m6A-dependent modification. | Tissue Cell | 2023 | 37536262 | PubTator, text mining | PubMed |
| Methyltransferase-like proteins in cancer biology and potential therapeutic targeting. | J Hematol Oncol | 2023 | 37533128 | PubTator, text mining | PubMed |
| Identification of the relationship between single-cell N6-methyladenosine regulators and the infiltrating immune cells in esophageal carcinoma. | Heliyon | 2023 | 37529341 | PubTator, text mining | PubMed |
| The therapeutic targets of N6-methyladenosine (m6A) modifications on tumor radioresistance. | Discov Oncol | 2023 | 37522921 | PubTator, text mining | PubMed |
| A Ferroptosis-Related lncRNAs Signature Predicts Prognosis of Colon Adenocarcinoma. | Life (Basel) | 2023 | 37511932 | PubTator, text mining | PubMed |
| Infection Meets Inflammation: N6-Methyladenosine, an Internal Messenger RNA Modification as a Tool for Pharmacological Regulation of Host-Pathogen Interactions. | Biomolecules | 2023 | 37509095 | PubTator, text mining | PubMed |
| Comprehensive analysis of m6A regulators associated with immune infiltration in Hepatitis B virus-related hepatocellular carcinoma. | BMC Gastroenterol | 2023 | 37507670 | PubTator, text mining | PubMed |
| Diagnostic value and immune infiltration characterization of YTHDF2 as a critical m6A regulator in osteoarthritic synovitis. | J Orthop Surg Res | 2023 | 37496062 | PubTator, text mining | PubMed |
| Multilevel regulation of N6-methyladenosine RNA modifications: Implications in tumorigenesis and therapeutic opportunities. | Genes Dis | 2023 | 37492716 | PubTator, text mining | PubMed |
| The yeast RNA methylation complex consists of conserved yet reconfigured components with m6A-dependent and independent roles. | Elife | 2023 | 37490041 | PubTator, text mining | PubMed |
| Novel insight into RNA modifications in tumor immunity: Promising targets to prevent tumor immune escape. | Innovation (Camb) | 2023 | 37485079 | PubTator, text mining | PubMed |
| N6-methyladenosine RNA modification: an emerging molecule in type 2 diabetes metabolism. | Front Endocrinol (Lausanne) | 2023 | 37484964 | PubTator, text mining | PubMed |
| RNautophagic regulation of DNMT3a-dependent DNA methylation by Linc00942 enhances chemoresistance in gastric cancer. | Clin Transl Med | 2023 | 37477089 | PubTator, text mining | PubMed |
| Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer. | BMC Cancer | 2023 | 37474926 | PubTator, text mining | PubMed |
| N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment. | Front Endocrinol (Lausanne) | 2023 | 37469973 | PubTator, text mining | PubMed |
| Establishment of a prognostic model based on m6A regulatory factors and stemness of hepatocellular carcinoma using RNA-seq data and scRNA-seq data. | J Cancer Res Clin Oncol | 2023 | 37466793 | PubTator, text mining | PubMed |
| A novel DNA damage repair-related gene signature predicting survival, immune infiltration and drug sensitivity in cervical cancer based on single cell sequencing. | Front Immunol | 2023 | 37449209 | PubTator, text mining | PubMed |
| The Regulation of m6A Modification in Glioblastoma: Functional Mechanisms and Therapeutic Approaches. | Cancers (Basel) | 2023 | 37444417 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23091/papers?page=12